Clinical Trial: A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy

U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07816237) titled 'A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy' on Sept. 04.

Brief Summary: A study of the efficacy and safety of VSA012 Injection compared to eculizumab for 24 weeks in patients with PNH.

Study Start Date: Oct. 29

Study Type: INTERVENTIONAL

Condition: Paroxysmal Nocturnal Hemoglobinuria, PNH

Intervention: DRUG: VSA012

VSA012 Injection

DRUG: Eculizumab (Soliris(R))

Eculizumab injection

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Bisi...